{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:32:50Z","timestamp":1777858370875,"version":"3.51.4"},"reference-count":110,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015303","name":"otsuka pharmaceutical development and commercialization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015303","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Switching between versions of medication products happens commonly despite challenges in achieving bioequivalence and therapeutic equivalence. Central nervous system and psychiatric drugs, especially those that are technically demanding to manufacture and have complex pharmacokinetic properties, such as long-acting injectables (LAIs), pose particular challenges to bioequivalence and safe and efficacious drug switching.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>To assess whether drugs deemed \u201cbioequivalent\u201d are truly interchangeable in drug switching.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We assessed the published literature from January 2017 through June 2023 on PubMed using the MeSH terms \u201cdrugs, generic\u201d OR \u201cequivalency, generic\u201d combined with terms for different psychiatric drug classes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>While most of the published studies returned in the search found that switching drug products was safe and clinically comparable, data on most drug classes other than those primarily indicated in the treatment of seizure disorder were sparse. Some studies also provided evidence that real-world outcomes such as adherence and hospitalizations may also be affected by switching. In addition, a review of bioequivalence testing guidance showed inconsistency across agencies and a lack of product-specific guidance from Health Canada, which raises questions about potential claims of bioequivalence for more complex products such as LAIs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Overall, given the difficulty in treating mental health disorders, prescribers should be cautious when switching products and formulations in a patient who has been stabilized on a drug.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/02698811241301219","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T05:12:22Z","timestamp":1738300342000},"page":"81-91","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Challenges for switching central nervous system and psychiatric medication products: A review of the literature"],"prefix":"10.1177","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4348-0855","authenticated-orcid":false,"given":"Ric M","family":"Procyshyn","sequence":"first","affiliation":[{"name":"Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada"},{"name":"British Columbia Mental Health and Substance Use Research Institute, Vancouver, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6169-2595","authenticated-orcid":false,"given":"Martin A","family":"Katzman","sequence":"additional","affiliation":[{"name":"START Clinic for Mood and Anxiety Disorders, Toronto, ON, Canada"},{"name":"Adler Graduate Professional School, Toronto, ON, Canada"},{"name":"Department of Psychiatry, Northern Ontario School of Medicine, Thunder Bay, ON, Canada"},{"name":"Department of Psychology, Lakehead University, Thunder Bay, ON, Canada"},{"name":"The Edward S. Rogers Sr. Department of Electrical and Computer Engineering, University of Toronto, Toronto, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard C","family":"Margolese","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, McGill University, Montreal, QC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ofer","family":"Agid","sequence":"additional","affiliation":[{"name":"Center for Addiction and Mental Health, Toronto, ON, Canada"},{"name":"Department of Psychiatry, University of Toronto, Toronto, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre M","family":"Blier","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, McGill University, Montreal, QC, Canada"},{"name":"Royal Ottawa Institute of Mental Health Research, University of Ottawa, Ottawa, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,1,31]]},"reference":[{"key":"bibr1-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2022.2050109"},{"key":"bibr2-02698811241301219","unstructured":"American Medical Association (2023) AMA Strengthens Policy to Address Growing National Drug Shortages [Press Release]. Available at: https:\/\/www.ama-assn.org\/press-center\/press-releases\/ama-strengthens-policy-address-growing-national-drug-shortages (accessed 25 September 2024)."},{"key":"bibr3-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.01007.x"},{"key":"bibr4-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-022-03391-y"},{"key":"bibr5-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.0497"},{"key":"bibr6-02698811241301219","first-page":"167","volume":"28","author":"Blier P","year":"2003","journal-title":"J Psychiatry Neurosci"},{"key":"bibr7-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1177\/0269881107081126"},{"key":"bibr8-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1080\/13651501.2018.1508724"},{"key":"bibr9-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2013.07.004"},{"key":"bibr10-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(03)80157-1"},{"key":"bibr11-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2019.02.017"},{"key":"bibr12-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2011.106"},{"key":"bibr13-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1177\/2045125314540297"},{"key":"bibr14-02698811241301219","first-page":"180","volume":"24","author":"Buxbaum JD","year":"2018","journal-title":"Am J Manag Care"},{"key":"bibr15-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.03.002"},{"key":"bibr16-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-017-0459-1"},{"key":"bibr17-02698811241301219","volume-title":"Lithium","author":"Chokhawala K","year":"2023"},{"key":"bibr18-02698811241301219","doi-asserted-by":"publisher","DOI":"10.9740\/mhc.n186977"},{"key":"bibr19-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001512"},{"key":"bibr20-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00779-5"},{"key":"bibr21-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-020-2781-6"},{"key":"bibr22-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2020.106936"},{"key":"bibr23-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2022.108587"},{"key":"bibr24-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2018.11.039"},{"key":"bibr25-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002763"},{"key":"bibr26-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-5949.2010.00210.x"},{"key":"bibr27-02698811241301219","first-page":"172","volume":"4","author":"Dickson M","year":"2004","journal-title":"Discov Med"},{"key":"bibr28-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhealeco.2016.01.012"},{"key":"bibr29-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.121.000994"},{"key":"bibr30-02698811241301219","unstructured":"European Medicines Agency (2010) Guideline on the Investigation of Bioequivalence. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2010\/01\/WC500070039.pdf (accessed 25 September 2024)."},{"key":"bibr31-02698811241301219","unstructured":"European Medicines Agency (2013) Concept Paper on the Development of Product-Specific Guidance on Demonstration of Bioequivalence. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/concept-paper-development-product-specific-guidance-demonstration-bioequivalence_en.pdf (accessed 25 September 2024)."},{"key":"bibr32-02698811241301219","unstructured":"European Medicines Agency (2017) Paliperidone Palmitate Depot Suspension for Injection 25 mg, 50 mg, 75 mg, 100 mg and 150 mg Product Specific Bioequivalence Guidance. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/paliperidone-palmitate-depot-suspension-injection-25-mg-50-mg-75-mg-100-mg-150-mg-product-specific_en.pdf (accessed 25 September 2024)."},{"key":"bibr33-02698811241301219","unstructured":"European Medicines Agency (2022) ICH Guideline M10 on Bioanalytical Method Validation and Study Sample Analysis Step 5. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-guideline-m10-bioanalytical-method-validation-step-5_en.pdf (accessed 25 September 2024)."},{"key":"bibr34-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0000000000000250"},{"key":"bibr35-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2022.01.017"},{"key":"bibr36-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2022.106296"},{"key":"bibr37-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2018.06.020"},{"key":"bibr38-02698811241301219","volume-title":"Lamictal [Package Insert]","author":"GlaxoSmithKline","year":"2018"},{"key":"bibr39-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1023"},{"key":"bibr40-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.684"},{"key":"bibr41-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12931"},{"key":"bibr42-02698811241301219","doi-asserted-by":"publisher","DOI":"10.3390\/molecules23071719"},{"key":"bibr43-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1136\/bmjinnov-2019-000370"},{"key":"bibr44-02698811241301219","unstructured":"Health Canada (2018) Guidance Document: Comparative Bioavailability Standards: Formulations Used for Systemic Effects. Available at: https:\/\/www.canada.ca\/content\/dam\/hc-sc\/migration\/hc-sc\/dhp-mps\/alt_formats\/pdf\/prodpharma\/applic-demande\/guide-ld\/bio\/comparative-bioavailability-standards-formulations-used-systemic-effects.pdf (accessed 25 September 2024)."},{"key":"bibr45-02698811241301219","unstructured":"Health Canada (2019) Venlafaxine XR Product Recall (2019-12-20). Available at: https:\/\/recalls-rappels.canada.ca\/en\/alert-recall\/venlafaxine-xr-product-recall-2019-12-20 (accessed 25 September 2024)."},{"key":"bibr46-02698811241301219","unstructured":"Health Canada (2023) Guidance Document: Conduct and Analysis of Comparative Bioavailability Studies. Available at: https:\/\/www.canada.ca\/content\/dam\/hc-sc\/documents\/services\/drugs-health-products\/drug-products\/applications-submissions\/guidance-documents\/bioavailability-bioequivalence\/conduct-analysis-comparative.pdf (accessed 25 September 2024)."},{"key":"bibr47-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1111\/epi.14439"},{"key":"bibr48-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2020.2166"},{"key":"bibr49-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-021-09778-5"},{"key":"bibr50-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2017.06.020"},{"key":"bibr51-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyaa041"},{"key":"bibr52-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-022-00726-w"},{"key":"bibr53-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1309"},{"key":"bibr54-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1888"},{"key":"bibr55-02698811241301219","first-page":"14","volume":"62","author":"Kluznik JC","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"bibr56-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2017.05.010"},{"key":"bibr57-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25353"},{"key":"bibr58-02698811241301219","unstructured":"Lee K (2020) Federal Court Upholds Validity of Janssen\u2019s Paliperidone Palmitate Patent. Available at: https:\/\/www.jdsupra.com\/legalnews\/federal-court-upholds-validity-of-94543\/ (accessed 25 September 2024)."},{"key":"bibr59-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000313154.55518.25"},{"key":"bibr60-02698811241301219","volume":"15","author":"Li C","year":"2020","journal-title":"PLoS One"},{"key":"bibr61-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-017-0795-1"},{"key":"bibr62-02698811241301219","unstructured":"Lionberger R (2021) Generic Drugs in the 21st Century: FDA\u2019s Actions Create Transparency and Value for Complex Generic Product Development. Available at: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/generic-drugs-21st-century-fdas-actions-create-transparency-and-value-complex-generic-product (accessed 25 September 2024)."},{"key":"bibr63-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-023667"},{"key":"bibr64-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2017.03.012"},{"key":"bibr65-02698811241301219","first-page":"23","author":"Meyer MC","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"bibr66-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-009-9142-z"},{"key":"bibr67-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1016\/j.nrl.2016.03.012"},{"key":"bibr68-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.824"},{"key":"bibr69-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16802"},{"key":"bibr70-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000711"},{"key":"bibr71-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2019.04.029"},{"key":"bibr72-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-022-01223-5"},{"key":"bibr73-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.07.001"},{"key":"bibr74-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1177\/10398562211057872"},{"key":"bibr75-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1007\/s40199-022-00440-0"},{"key":"bibr76-02698811241301219","doi-asserted-by":"publisher","DOI":"10.18433\/jpps30669"},{"key":"bibr77-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2017.06.007"},{"key":"bibr78-02698811241301219","volume":"30","author":"Ratri DMN","year":"2020","journal-title":"J Basic Clin Physiol Pharmacol"},{"key":"bibr79-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2017.04.017"},{"key":"bibr80-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau6753"},{"key":"bibr81-02698811241301219","doi-asserted-by":"publisher","DOI":"10.2147\/PRBM.S371991"},{"key":"bibr82-02698811241301219","first-page":"12","volume":"3","author":"Riordan HJ","year":"2012","journal-title":"J Clin Stud"},{"key":"bibr83-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.107804"},{"key":"bibr84-02698811241301219","first-page":"109","volume":"57","author":"Rosenthal J","year":"2008","journal-title":"J Fam Pract"},{"key":"bibr85-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.928"},{"key":"bibr86-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2019.1519399"},{"key":"bibr87-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-021-03149-y"},{"key":"bibr88-02698811241301219","unstructured":"Sun Pharmaceutical Industries (2023) Bupropion Hydrochloride Extended-Release Recall Notice. Available at: https:\/\/www.pharmacy.ca.gov\/about\/recall_alerts\/052223_sun.pdf (accessed 25 September 2024)."},{"key":"bibr89-02698811241301219","unstructured":"Thomas K (2020) Major Insurers Pledge $55 Million to Try to Lower Generic Drug Prices. Available at: https:\/\/www.nytimes.com\/2020\/01\/23\/health\/drug-prices-generics.html (accessed 25 September 2024)."},{"key":"bibr90-02698811241301219","doi-asserted-by":"publisher","DOI":"10.5414\/CP201845"},{"key":"bibr91-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13568"},{"key":"bibr92-02698811241301219","unstructured":"U.S. Food and Drug Administration (2001) Guidance for Industry. Statistical Approaches to Establishing Bioequivalence. Available at: https:\/\/www.fda.gov\/downloads\/drugs\/guidances\/ucm070244.pdf (accessed 25 September 2024)."},{"key":"bibr93-02698811241301219","unstructured":"U.S. Food and Drug Administration (2010) Guidance for Industry ANDAs: Impurities in Drug Products. Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/andas-impurities-drug-products (accessed 25 September 2024)."},{"key":"bibr94-02698811241301219","unstructured":"U.S. Food and Drug Administration (2013) Draft Guidance on Bupropion Hydrochloride. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/psg\/Bupropion_HCl_ERtab_20358_20711_RV03-13.pdf (accessed 25 September 2024)."},{"key":"bibr95-02698811241301219","unstructured":"U.S. Food and Drug Administration (2014) Draft Guidance on Aripiprazole. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/psg\/Aripiprazole_ERinjecsusp_202971_RC12-14.pdf (accessed 25 September 2024)."},{"key":"bibr96-02698811241301219","unstructured":"U.S. Food and Drug Administration (2016a) Draft Guidance on Olanzapine Pamoate. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/psg\/Olanzapine_Intramuscular%20ER%20suspension_RLD22173_RC01-16.pdf (accessed 25 September 2024)."},{"key":"bibr97-02698811241301219","unstructured":"U.S. Food and Drug Administration (2016b) Draft Guidance on Risperidone. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/psg\/Risperidone_intramuscular%20injection_RLD%2021346_RV08-16%20separate%20post.pdf (accessed 25 September 2024)."},{"key":"bibr98-02698811241301219","unstructured":"U.S. Food and Drug Administration (2017) FY2015 Regulatory Science Research Report: Narrow Therapeutic Index Drugs [Press Release]. Available at: https:\/\/www.fda.gov\/industry\/generic-drug-user-fee-amendments\/fy2015-regulatory-science-research-report-narrow-therapeutic-index-drugs (accessed 25 September 2024)."},{"key":"bibr99-02698811241301219","unstructured":"U.S. Food and Drug Administration (2021a) Draft Guidance on Paliperidone Palmitate. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/psg\/PSG_207946.pdf (accessed 25 September 2024)."},{"key":"bibr100-02698811241301219","unstructured":"U.S. Food and Drug Administration (2021b) Generic Drugs: Questions & Answers. Available at: https:\/\/www.fda.gov\/drugs\/frequently-asked-questions-popular-topics\/generic-drugs-questions-answers (accessed 25 September 2024)."},{"key":"bibr101-02698811241301219","unstructured":"U.S. Food and Drug Administration (2022) FDA Product-Specific Guidance Snapshot. Available at: https:\/\/www.fda.gov\/media\/150142\/download (accessed 25 September 2024)."},{"key":"bibr102-02698811241301219","unstructured":"U.S. Food and Drug Administration (2023) Draft Guidance on Paliperidone Palmitate. Available at: https:\/\/pink.pharmaintelligence.informa.com\/-\/media\/supporting-documents\/pink-sheet\/2023\/06\/p0623fda_62.pdf (accessed 25 September 2024)."},{"key":"bibr103-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1353"},{"key":"bibr104-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-020-01023-2"},{"key":"bibr105-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1212969"},{"key":"bibr106-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1P482"},{"key":"bibr107-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13826"},{"key":"bibr108-02698811241301219","doi-asserted-by":"publisher","DOI":"10.5414\/CP203864"},{"key":"bibr109-02698811241301219","doi-asserted-by":"publisher","DOI":"10.2217\/pgs-2020-0134"},{"key":"bibr110-02698811241301219","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1282"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811241301219","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811241301219","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811241301219","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:11:58Z","timestamp":1777507918000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811241301219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,31]]},"references-count":110,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1177\/02698811241301219"],"URL":"https:\/\/doi.org\/10.1177\/02698811241301219","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,31]]}}}